HIV and opioid treatment study halted early – what we know

NCT ID NCT04480554

Terminated Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether different medications for opioid use disorder (methadone, buprenorphine/naloxone, or naltrexone) could reduce immune system inflammation in people with HIV. Researchers measured changes in blood markers of immune activation over 24 weeks. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Methadone, buprenorphine/naloxone, or extended-release naltrexone
What this could lead to: If successful, this could help doctors choose the best medication for opioid use disorder to improve immune recovery in people with HIV.
What could go wrong: The study was terminated early, so results are limited. It was a small Phase 2 trial, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIRETROVIRAL TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease Inflammation inflammatory disease opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIRETROVIRAL TREATMENT BUPRENORPHINE HIV-1-INFECTION IMMUNE ACTIVATION INFLAMMATION METHADONE NALTREXONE OPIOID-USE DISORDER

HIV and opioid treatment study halted early – what we know

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions